Company Analysis
Sign in

Telix Pharmaceuticals Limited (TLX)

Nasdaq: TLX · Pharmaceutical Preparations · North Melbourne, AU · filing with the SEC since 2024
Full chart Alerts Compare
Grade6.6
◀ Past 7.7● Present 6.8▶ Future 5.2
2 est.
OverviewBusinessFinancialsGradeForecastSentimentOwnershipPeopleFilingsPatents Chart
The companyfiscal 2025, as filed
Revenue$804M+55.6%
Net income-$7.1M-121.2%
Earnings per share$-0.02-121.6%
Operating cash flow-$17.3M-162.9%
Cash$142M-67.8%
Debt$405M+14.6%
Shareholders’ equity$415M+17.7%
Shares, diluted337.9M-2.1%
Return on equity-1.7%
The recordfrom its filings
Filings in 202647
Newest filingOct 29 · 6-K
Annual reportFeb 20, 2026
Quarterly reportn/a
Next report due20-F by Apr 30
Insider sales, 12 months$0.00
Insider buys, 12 months$1.0M
Patents granted6
Filer categoryLarge accelerated filer
Left: the newest annual report, with the change on the year before. Right: counted from the company's own filings with the SEC.
Revenue and net income by fiscal yearRevenueNet income
232425
As filed, in USD. Nothing here is a forecast.

News

Sep 14, 2026 · SEC EDGAR · Form 4
Insider trade report
Open the filing on sec.gov
An outside story is shown by its headline, its source and its link only. The SI reads the page when you ask it to break one down.
SI Assistanton TLX · research, not advice